Leukemia Clinical Trials

CLINICAL TRIAL 19724
Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 19724
Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)

CLINICAL TRIAL 20632
A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients with Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)
Condition: Malignant Hematology
Intervention: FK506 (Tacrolimus); MESNA (); PBSC (); Tacrolimus (); Thiotepa (Thioplex); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate ()

CLINICAL TRIAL 20632
A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients with Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)
Condition: Malignant Hematology
Intervention: FK506 (Tacrolimus); MESNA (); PBSC (); Tacrolimus (); Thiotepa (Thioplex); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate ()

CLINICAL TRIAL 20737
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release
Condition: Malignant Hematology
Intervention: cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); lisocabtagene maraleucel ()

CLINICAL TRIAL 20733
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzomab Ozogamicin (a conjugated anti-CD22 monoclonal antibody) to Frontline Therapy in Young Adults (ages 18-39 years) with Newly Diagnosed Precusor B-cell ALL
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 20794
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: Safety and Biomarker Analysis
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab)

CLINICAL TRIAL 20870
Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
Condition: Gynecological Tumor
Intervention: Aspirin/Placebo (); Avastin (Bevacizumab); Bevacizumab (); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin (); paclitaxel ()

CLINICAL TRIAL 21192
A Phase 2 Study of the Combination Dostarlimab with Niraparib In Patients with Penile Carcinoma Who Have Progressed Following Chemotherapy
Condition: Genitourinary
Intervention: Dostarlimab (); Niraparib (); TSR-042 (Dostarlimab)

CLINICAL TRIAL 21213
A Single-Arm, Open-Label Phase 1b Study of Hyper-CVAD + Calaspargase pegol in Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia
Condition: Malignant Hematology
Intervention: Calaspargase pegol ()

CLINICAL TRIAL 21416
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Condition: Malignant Hematology
Intervention: CLN-049 (); Diphenhydramine (); Hydrocortisone (); Paracetamol (); acetaminophen ()

CLINICAL TRIAL 21664
Phase 1b/3 z=Global, Randomized, Controlled, Open-Label Trial Comparing Treatment with RYZ101 to Standard of Care (SoC) Therapy in Subjects with Inoperable, Advanced, Somatostatin Receptor Expressing (SSTR+), Well-Differentiated Gastro-Enteropancreatic Neuroendocrine Tumors (GEP-NETs) that have Progressed Following Prior 177Lulabelled Somatostatin Analogue (177Lu-SSA) Therapy (ACTION-1).
Condition: Gastrointestinal Tumor
Intervention: Amino acids (); Granisetron (); Lanreotide (); Ondansetron (); RYZ101 (); Sunitinib (); Zofran (Ondansetron); everolimus (RAD001); octreotide LAR ()

CLINICAL TRIAL 21752
Chimeric Antigen Receptor T-Cell Therapy: Neurocognitive Effects and Patient-Reported Outcomes
Condition: Multiple
Intervention:

CLINICAL TRIAL 21752
Chimeric Antigen Receptor T-Cell Therapy: Neurocognitive Effects and Patient-Reported Outcomes
Condition: Multiple
Intervention:

CLINICAL TRIAL 21763
MRKR-21-401-OTS - A Phase 1 Study of Allogeneic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cells (MT-401-OTS) Administered to Patients with Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)
Condition: Malignant Hematology
Intervention: Azacitidine (5-azacitidine); Bendamustine (); MESNA (); MT-401-OTS (); cyclophosphamide (); cytoxan (cyclophosphamide); decitabine (5-aza-2'-deoxycytidine); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 21790
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
Condition: Gastrointestinal Tumor
Intervention: Atezolizumab (Tecentriq); Etoposide (); Paraplatin (carboplatin); carboplatin (); cisplatin (); etoposide ()

CLINICAL TRIAL 21887
A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes
Condition: Malignant Hematology
Intervention: ASTX727 (); Itacitinib (); Jakafi (Ruxolitinib); Ruxolitinib ()

CLINICAL TRIAL 21887
A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes
Condition: Malignant Hematology
Intervention: ASTX727 (); Itacitinib (); Jakafi (Ruxolitinib); Ruxolitinib ()

CLINICAL TRIAL 21956
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
Condition: Immunotherapy
Intervention:

CLINICAL TRIAL 21970
A multicenter, open-label, first-in human (FIH), multiple expansion cohort, Phase 1/2 study to evaluate the safety and efficacy of DR-01 in adult subjects with large granular lymphocytic leukemia
Condition: Malignant Hematology
Intervention: DR-01 ()

CLINICAL TRIAL 21997
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Condition: Cutaneous
Intervention: Not Applicable (); Vismodegib (Erivedge)

CLINICAL TRIAL 22102
A Phase 1/2, First in Human Multicenter Study of Emi-Le in Patients with Solid Tumors
Condition: Multiple
Intervention: Emiltatug Ledadotin (); XMT-1660 ()

CLINICAL TRIAL 22134
AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participants with Immune Checkpoint Inhibitor Associated Myocarditis
Condition: Immunotherapy
Intervention: Abatacept (); Corticosteroids (); Placebo ()

CLINICAL TRIAL 22191
Discontinuation of Hypomethylating Agent and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Have Achieved Negative Measurable Residual Disease (MRD)
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 22191
Discontinuation of Hypomethylating Agent and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Have Achieved Negative Measurable Residual Disease (MRD)
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 22263
A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or B-cell Non-Hodgkin Lymphoma
Condition: Malignant Hematology
Intervention: AS-1763 ()

CLINICAL TRIAL 22286
Phase 2 Study of KTE-X19 in MRD Positive B-ALL
Condition: Malignant Hematology
Intervention: KTE-X19 (); Vincristine (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22286
Phase 2 Study of KTE-X19 in MRD Positive B-ALL
Condition: Malignant Hematology
Intervention: KTE-X19 (); Vincristine (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22305
First-in-Human Study of STX-478, a Mutant-Selective PI3Ka Inhibitor as Monotherapy and in Combination with Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: 772256 (Palbociclib); Abemaciclib (); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Imlunestrant (); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Letrozole (); Metformin (); Palbociclib (); Ribociclib (); STX478-101 (); Tamoxifen (); fulvestrant ()

CLINICAL TRIAL 22367
The Impact Of Inflammation On HSPC Composition And Disease Progression In Chronic Myelomonocytic Leukemia (CMML INTERCEPT STUDY) SUB-TITLE: Intercepting CMML Disease Progression Driven by Acute Inflammation
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 22469
A Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)
Condition: Malignant Hematology
Intervention: AZD0486 ()

CLINICAL TRIAL 22483
Phase 1b/2a Study of GNS561 in Combination with Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
Condition: Gastrointestinal Tumor
Intervention: Ezurpimtrostat (GNS561) (); GSK1120212 (Trametinib); Trametinib ()

CLINICAL TRIAL 22604
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 22685
Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors
Condition: Multiple
Intervention: RMC-6236 (Daraxonrasib); RMC-9805 (Zoldonrasib)

CLINICAL TRIAL 22696
Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia SCOPE-Leukemia
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 22696
Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia SCOPE-Leukemia
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23060
A Controlled Multi-Arm Phase 1 Umbrella Study Evaluating the Safety and Feasibility of T-Cell Receptor Engineered Donor T-Cells Targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 Positive Patients Undergoing Haploidentical Allogeneic Peripheral Blood Stem Cell Transplantation
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23060
A Controlled Multi-Arm Phase 1 Umbrella Study Evaluating the Safety and Feasibility of T-Cell Receptor Engineered Donor T-Cells Targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 Positive Patients Undergoing Haploidentical Allogeneic Peripheral Blood Stem Cell Transplantation
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23055
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FB849 Administered in Subjects with Advanced Solid Tumors Alone and in Combination with Pembrolizumab
Condition: Genitourinary
Intervention: FB849 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 23058
A Phase I/II Study of Quizartinib in Combination with Decitabine and Venetoclax for the Treatment of Patients with Acute Myeloid Leukemia (AML)
Condition: Malignant Hematology
Intervention: GDC-0199 (Venetoclax); Quizartinib (); Venetoclax (); decitabine (5-aza-2'-deoxycytidine)

CLINICAL TRIAL 23066
An Open-Label, Multi-Center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-Targeting T Cell Engager, in Patients with Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer and in Patients with Other Relapsed/Refractory Neuroendocrine Carcinoma DAREON-5
Condition: Gastrointestinal Tumor
Intervention: BI 764532 ()

CLINICAL TRIAL 23067
Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-positive Endometrioid Endometrial Cancers
Condition: Gynecological Tumor
Intervention: Alpelisib (); Faslodex (fulvestrant); fulvestrant ()

CLINICAL TRIAL 23143
Trends and Outcomes in HIV-positive Patients Undergoing Treatment for Invasive or Preinvasive Cervical and Other Gynecologic Neoplasias
Condition: Gynecological Tumor
Intervention:

CLINICAL TRIAL 23154
A Prospective, Multicenter, Randomized, Open-Label, Phase II Study of Salvage BCL2i Plus CLAG-M in Relapsed or Refractory Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: Cladribine (); Cytarabine (Cytosine Arabinoside); G-CSF (); GDC-0199 (Venetoclax); Novantrone (mitoxantrone); Venetoclax (); mitoxantrone ()

CLINICAL TRIAL 23176
A Phase 2, randomised, open label, multicentre study of an intraperitoneal alpha-emitting radionuclide therapy (Radspherin®) in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are homologous recombination proficient and scheduled to undergo neoadjuvant chemotherapy and interval debulking surgery
Condition: Gynecological Tumor
Intervention: Radspherin ()

CLINICAL TRIAL 23220
A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
Condition: Malignant Hematology
Intervention: REM-422 ()

CLINICAL TRIAL 23226
A Prospective Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as an Adjunctive and Maintenance Treatment in Adult Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Condition: Malignant Hematology
Intervention: Mocravimod (); Placebo ()

CLINICAL TRIAL 23226
A Prospective Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as an Adjunctive and Maintenance Treatment in Adult Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Condition: Malignant Hematology
Intervention: Mocravimod (); Placebo ()

CLINICAL TRIAL 23233
Evaluating the correlation between clonal hematopoiesis chemotherapy induced peripheral neuropathy in patients with gastrointestinal malignancies exposed to oxaliplatin
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 23241
Factors Determining Ovarian Cancer Outcomes Following Heated Intraperitoneal Chemotherapy (HiPEC)
Condition: Gynecological Tumor
Intervention:

CLINICAL TRIAL 23253
A Phase 1 Dose Escalation and Expansion Study of Orca-Q, an Engineered Donor Graft Derived from Mobilized Peripheral Blood, in Recipients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
Condition: Malignant Hematology
Intervention: Orca-Q ()

CLINICAL TRIAL 23284
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia
Condition: Malignant Hematology
Intervention: Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); MESNA (); Mycophenolate Mofetil (); Radiotherapy (); Tacrolimus (); Thymoglobulin (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23308
A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Administered as Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Condition: Malignant Hematology
Intervention: AJ1-11095 (); LY5830966 ()

CLINICAL TRIAL 23318
Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
Condition: Sarcoma
Intervention: Pembrolizumab (Keytruda)

CLINICAL TRIAL 23652
A Phase 1, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory (R/R) CD19+ hematologic malignancies
Condition: Malignant Hematology
Intervention: Rapamycin (Sirolimus); UB-VV111 ()

CLINICAL TRIAL 23362
DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer
Condition: Gynecological Tumor
Intervention: Paraplatin (carboplatin); Pembrolizumab (Keytruda); Rilvegostomig (); T-Dxd (); Taxol (paclitaxel); carboplatin (); paclitaxel ()

CLINICAL TRIAL 23378
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of AVZO-021 as a single agent and in combination therapy in patients with advanced solid tumors
Condition: Breast
Intervention: 772256 (Palbociclib); AVZO-021 (); Abemaciclib (); Faslodex (fulvestrant); Femara (Letrozole); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Letrozole (); Palbociclib (); Paraplatin (carboplatin); Ribociclib (); Sacituzumab Govitecan (); carboplatin (); fulvestrant ()

CLINICAL TRIAL 23380
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod CAR T Protducts in Heterozygous HLA-A*02 Adult with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Condition: Thoracic
Intervention: A2B543 (); A2B694 (); IL-2 (Interleukin-2); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23405
ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Condition: Genitourinary
Intervention: AMP-514 (Durvalumab); Durvalumab (); IPH2201 (Monalizumab); MEDI4736 (Durvalumab); Monalizumab ()

CLINICAL TRIAL 23415
Societal, Ancestry, Molecular and Biological Analyses of Inequalities: SAMBAI
Condition: Multiple
Intervention:

CLINICAL TRIAL 23436
A Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in Federal Qualified Health Centers
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 23489
Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23489
Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23502
BMT-CARE: Multimodal Psychosocial Intervention for Caregivers of Patients Undergoing Hematopoietic Stem Cell Transplantation
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23502
BMT-CARE: Multimodal Psychosocial Intervention for Caregivers of Patients Undergoing Hematopoietic Stem Cell Transplantation
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23448
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients with Solid Tumors with KRASG12D Mutation
Condition: Multiple
Intervention: Cemiplimab (); Cetuximab (); Erbitux (Cetuximab); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Pembrolizumab (Keytruda); QTX3034 (); REGN2810 (Cemiplimab); gemcitabine (); mFOLFOX6 ()

CLINICAL TRIAL 23453
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Condition: Malignant Hematology
Intervention: AZD0486 ()

CLINICAL TRIAL 23456
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (CTN 2203)
Condition: Immunotherapy
Intervention: Alkeran (Melphalan); Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); Jakafi (Ruxolitinib); Melphalan (); Mycophenolate Mofetil (); Radiotherapy (); Ruxolitinib (); Tacrolimus (); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate ()

CLINICAL TRIAL 23456
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (CTN 2203)
Condition: Immunotherapy
Intervention: Alkeran (Melphalan); Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); Jakafi (Ruxolitinib); Melphalan (); Mycophenolate Mofetil (); Radiotherapy (); Ruxolitinib (); Tacrolimus (); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate ()

CLINICAL TRIAL 23477
Phase 1 Study of Asciminib Maintenance Therapy Following Allogeneic Stem Cell Transplant or Chimeric Antigen Receptor T Cell Therapy (CAR T) to Prevent Relapse in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Condition: Malignant Hematology
Intervention: Asciminib ()

CLINICAL TRIAL 23479
A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: BL-M11D1 ()

CLINICAL TRIAL 23478
PROSPERA: A Randomized Phase 2 Study of Pacritinib vs. Hydroxyurea in Patients with Proliferative Advanced CMML
Condition: Malignant Hematology
Intervention: Hydroxyurea (Droxia); Pacritinib ()

CLINICAL TRIAL 23547
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogenic CAR-T Cell Therapy, in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma(T-RRex)
Condition: Malignant Hematology
Intervention: WU-CART-007 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23549
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); VET3-TGI ()

CLINICAL TRIAL 23519
Integration of Machine Learning and Genomics to Predict Outcomes for Newly Diagnosed, Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms: A Global Study of the PETAL Consortium
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23519
Integration of Machine Learning and Genomics to Predict Outcomes for Newly Diagnosed, Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms: A Global Study of the PETAL Consortium
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23539
Evaluating the correlation between clonal hematopoiesis and response to regorafenib and nivolumab in patients with refractory metastatic colorectal cancer
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 23597
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint Inhibitor Naïve Participants with Advanced or Metastatic Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: IFx-Hu2.0 (); Pembrolizumab (Keytruda); Placebo ()

CLINICAL TRIAL 23558
Predictors of Health-Related Quality of Life in Adults with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23558
Predictors of Health-Related Quality of Life in Adults with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23557
Distress in Family Caregivers of Inpatients with Malignant Hematology Diagnoses at Hospital Discharge
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23569
Perceptions and Experiences of Food Insecurity in Patients & Their Informal Caregivers Post Allogeneic Stem Cell Transplant
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23590
Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment versus Standard-Of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
Condition: Multiple
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); Radiotherapy ()

CLINICAL TRIAL 23591
Prediction of Radiotherapy Benefit Using Genomic-Adjusted Radiation Dose in Pediatric Low Grade Gliomas and Ependymomas
Condition: Neurologic Oncology
Intervention:

CLINICAL TRIAL 23595
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy
Condition: Malignant Hematology
Intervention: Azacitidine (5-azacitidine); Bleximenib/placebo (); GDC-0199 (Venetoclax); Venetoclax ()

CLINICAL TRIAL 23602
A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
Condition: Malignant Hematology
Intervention: AUTX-703 ()

CLINICAL TRIAL 23626
A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors
Condition: Gastrointestinal Tumor
Intervention: Paltusotine (); Paltusotine/Placebo ()

CLINICAL TRIAL 23636
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors
Condition: Gynecological Tumor
Intervention: XmAb541 ()

CLINICAL TRIAL 23640
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation
Condition: Malignant Hematology
Intervention: Azacitidine (5-azacitidine); Cytarabine (Cytosine Arabinoside); DSP-5336 (); Daunomycin (daunorubicin); GDC-0199 (Venetoclax); Gilteritinib (); Idarubicin (); Venetoclax (); Zevados (Idarubicin); daunorubicin ()

CLINICAL TRIAL 23645
PHASE 1 DOSE ESCALATION AND EXPANSION STUDY OF XB628 AS A SINGLE AGENT AND IN COMBINATION WITH ZANZALINTINIB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Condition: Multiple
Intervention: XB628 (); Zanzalintinib ()

CLINICAL TRIAL 23650
A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients with Relapsed or Resistant Acute Leukaemias
Condition: Malignant Hematology
Intervention: Azacitidine (5-azacitidine); GDC-0199 (Venetoclax); LBS-007 (); Venetoclax ()

CLINICAL TRIAL 23650
A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients with Relapsed or Resistant Acute Leukaemias
Condition: Malignant Hematology
Intervention: Azacitidine (5-azacitidine); GDC-0199 (Venetoclax); LBS-007 (); Venetoclax ()

CLINICAL TRIAL 23665
ProSalud: A Health Promotion Project to Reduce Cancer Risk in Latinos Living in Rural/Agricultural Communities within Moffitt's Catchment Area
Condition: Healthy Subjects
Intervention:

CLINICAL TRIAL 23660
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention:

CLINICAL TRIAL 23674
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
Condition: Malignant Hematology
Intervention: Elritercept/Placebo ()

CLINICAL TRIAL 23675
A Phase 1, Open-Label, Dose-escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants with Relapsed or Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia.
Condition: Malignant Hematology
Intervention: CBX-250 (); TKI ()

CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()

CLINICAL TRIAL 23716
AVENTINE-1: A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-1418 as a single agent and in combination therapy in patients with locally advanced or metastatic solid tumors
Condition: Multiple
Intervention: AVZO-1418 (); AZD9291 (Osimertinib); Osimertinib (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 23740
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23747
Evaluation of SSTR Subtype Expression in Brain Regions via IHC
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 23786
Unusual Causes of Familial and Early-Onset Cancer
Condition: Multiple
Intervention:

CLINICAL TRIAL 23750
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: Azacitidine (5-azacitidine); Cytarabine (Cytosine Arabinoside); Daunomycin (daunorubicin); GDC-0199 (Venetoclax); Venetoclax (); Ziftomenib/Placebo (); daunorubicin ()

CLINICAL TRIAL 23773
A Phase 1b/2 Study of AZD0120 (also known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B cell Maturation Antigen in Participants with Relapsed or Refractory AL Amyloidosis
Condition: Malignant Hematology
Intervention: AZD0120 ()

CLINICAL TRIAL 23782
Development of Novel Predictive Biomarkers to Enhance Utility of Cetuximab Therapy for Colorectal Cancer
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 23785
CASCADE: A Single-Arm, Open-Label Clinical Phase II Trial of the Safety and Immunogenicity of PDS0101 in People Living with HIV
Condition: N/A
Intervention:

CLINICAL TRIAL 23800
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel
Condition: Malignant Hematology
Intervention: Brexucabtagene Autoleucel ()

CLINICAL TRIAL 23814
A Phase 2 Trial of ORCA-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
Condition: Malignant Hematology
Intervention: ORCA-T (); Thiotepa (Thioplex); Total body irradiation (TBI) (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23814
A Phase 2 Trial of ORCA-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
Condition: Malignant Hematology
Intervention: ORCA-T (); Thiotepa (Thioplex); Total body irradiation (TBI) (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23821
Development of a peripheral blood assay to replace BM evaluation in cytopenia - a multi-Center observational study
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23829
A Phase 1/2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants with Unresectable Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: TAK-505 ()

CLINICAL TRIAL 23906
Open-Label, Cohort-Sequential Dose-Escalation and Dose-Confirmation Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of Domatinostat in Combination with Sirolimus in Adolescents and Adults with Relapsed, Refractory Sarcoma and Osteosarcoma
Condition: Sarcoma
Intervention: Domatinostat (); Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus ()

CLINICAL TRIAL 23921
A Phase 2 controlled randomized study of the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF intralesional injections for the treatment of locally advanced basal cell carcinoma patients
Condition: Cutaneous
Intervention: L19IL2 (); L19TNF ()

CLINICAL TRIAL 23930
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Condition: Genitourinary
Intervention: Abiraterone acetate (); Cabazitaxel (); Jevtana (Cabazitaxel); Taxotere (docetaxel); Xaluritamig (); Zytiga (Abiraterone acetate); docetaxel ()

CLINICAL TRIAL 23939
Distinguishing Breast and Cutaneous Tumors
Condition: Breast
Intervention:

CLINICAL TRIAL 23942
H. Jean Khoury Cure CML Consortium (HJKC3) Registry
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23942
H. Jean Khoury Cure CML Consortium (HJKC3) Registry
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23944
A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention: CC-4047 (Pomalidomide); Dexamethasone (); Inobrodib (); Pomalidomide ()

CLINICAL TRIAL 23948
An Observational Long-Term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23954
MYELOMATCH, MASTER SCREENING AND REASSESSMENT PROTOCOL (MSRP) FOR TIER ADVANCEMENT IN THE NCI MYELOMATCH CLINICAL TRIALS
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23954
MYELOMATCH, MASTER SCREENING AND REASSESSMENT PROTOCOL (MSRP) FOR TIER ADVANCEMENT IN THE NCI MYELOMATCH CLINICAL TRIALS
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23955
A RANDOMIZED PHASE II TRIAL OF ENASIDENIB-BASED THERAPIES VERSUS CEDAZURIDINE DECITABINE IN HIGHER-RISK IDH2-MUTATED MYELODYSPLASTIC SYNDROME: A MYELOMATCH SUB-STUDY
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23955
A RANDOMIZED PHASE II TRIAL OF ENASIDENIB-BASED THERAPIES VERSUS CEDAZURIDINE DECITABINE IN HIGHER-RISK IDH2-MUTATED MYELODYSPLASTIC SYNDROME: A MYELOMATCH SUB-STUDY
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23957
A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23957
A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23956
A MEASURABLE RESIDUAL DISEASE (MRD) FOCUSED, PHASE II STUDY OF VENETOCLAX PLUS CHEMOTHERAPY FOR NEWLY DIAGNOSED YOUNGER PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA: A TIER 1 MYELOMATCH CLINICAL TRIAL
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23956
A MEASURABLE RESIDUAL DISEASE (MRD) FOCUSED, PHASE II STUDY OF VENETOCLAX PLUS CHEMOTHERAPY FOR NEWLY DIAGNOSED YOUNGER PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA: A TIER 1 MYELOMATCH CLINICAL TRIAL
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23952
Treatment Effect vs. Tumor Progression - Quantitative Analysis Using Machine Learning
Condition: Neurologic Oncology
Intervention:

CLINICAL TRIAL 23965
A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single agent and in Combination with pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: BH3120 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 23972
A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Basal Cell Carcinoma patients progressed on or intolerant to systemic treatment
Condition: Cutaneous
Intervention: L19IL2 (); L19TNF ()

CLINICAL TRIAL 23980
A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)
Condition: Malignant Hematology
Intervention: ASTX727 (); Iadademstat ()

CLINICAL TRIAL 23983
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Condition: Malignant Hematology
Intervention: Mosunetuzumab (); Rituximab (); Rituximab Hyaluronidase ()

CLINICAL TRIAL 23996
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)
Condition: Sarcoma
Intervention: IDRX-42 (GSK6042981) (); Sunitinib ()

CLINICAL TRIAL 24046
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 24046
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 24017
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-103, a Nectin4/Trop2 ADC, as a single agent and in combination therapy in patients with locally advanced or metastatic urothelial cancer or other solid tumors
Condition: Genitourinary
Intervention: AVZO-103 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 24018
A Phase Ib study of Rezatapopt in combination with Azacitidine in patients with Relapsed/Refractory TP53Y220C mutant myeloid malignancies (Acute Myeloid Leukemia or Myelodysplastic syndrome)
Condition: Malignant Hematology
Intervention: Azacitidine (); Rezatapopt ()

CLINICAL TRIAL 24028
OMNIRAY, A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults with GRPR-Positive Advanced Solid Tumors
Condition: Multiple
Intervention: Abemaciclib (); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Imlunestrant (); LY2835219 (Abemaciclib); LY4257496 (); LY4257529 (); Letrozole (); Xeloda (capecitabine); capecitabine (); fulvestrant ()

CLINICAL TRIAL 24039
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) After Pancreaticoduodenectomy (Whipple Procedure): A Retrospective Chart Review
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 24043
Single Patient - Expanded Access Use of AMTAGVI
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 24071
Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients with Advanced KRAS G12V-Mutant Solid Tumors
Condition: Multiple
Intervention: Cetuximab (); Daraxonrasib (); Erbitux (Cetuximab); RMC-5127 (); RMC-6236 (Daraxonrasib)

CLINICAL TRIAL 50525
Characterization of Tumor Infiltrating Lymphocytes from Neuroendocrine neoplasms
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 24081
A Phase 1 Study of SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma
Condition: Multiple
Intervention: SynKIR-110 ()

CLINICAL TRIAL 24083
Incidence and risk factors for invasive fungal infections in patients with chronic graft-versus-host disease following allogeneic bone marrow transplantation.
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 24095
Phase 1/2a Open-Label Clinical Trial Evaluating VBC101, an EGFR and cMET Targeted Bi-Specific Antibody Drug Conjugate, in Participants With Advanced Solid Tumor Malignancies
Condition: Multiple
Intervention: VBC101 ()

CLINICAL TRIAL 24098
Geriatric Surgery Center Protocol
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 24103
A First-in-Human Phase 1 Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation
Condition: Multiple
Intervention: KST-6051 ()

CLINICAL TRIAL 24105
Parsing out the underutilization of parathyroidectomy – how are parathyroid lesions being found? A Multinational, multi-institutional analysis by the AHNS Endocrine Surgery Section Research Collaborative
Condition: Head & Neck
Intervention:

CLINICAL TRIAL 24107
A Phase 1 Study of ICP-248 in Combination with Azacitidine for the Treatment in Patients with Myeloid Malignancies
Condition: Malignant Hematology
Intervention: Azacitidine (); ICP-248 ()

CLINICAL TRIAL 24124
A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy
Condition: Malignant Hematology
Intervention: Azacitidine (); Azacitidine (5-azacitidine); GDC-0199 (Venetoclax); Pivekimab Sunirine (); Pivekimab Sunirine/Placebo (); Venetoclax ()

CLINICAL TRIAL 24126
A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination with Venetoclax and Azacitidine in Patients with Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML
Condition: Malignant Hematology
Intervention: Azacitidine (); GDC-0199 (Venetoclax); GFH-009 (); Venetoclax ()

CLINICAL TRIAL 24127
A Phase 1, Open-Label, Multi-Center, Safety and Efficacy Study of PRT12396 in Participants with Polycythemia Vera and Myelofibrosis
Condition: Malignant Hematology
Intervention: PRT12396 ()

CLINICAL TRIAL 24154
A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination with Imatinib in Participants with Advanced/Metastatic GI Stromal Tumor in 1st Line Setting
Condition: Sarcoma
Intervention: Imatinib (); KQB198 ()

CLINICAL TRIAL 24190
A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)
Condition: Multiple
Intervention: LY4337713 (); [18F] FAPI-74 (); [Ga-68]-FAPI-46 ()

CLINICAL TRIAL 24192
An Expanded Access Program for Orca-T Products That Are Out of Specification for Commercial Release
Condition: Malignant Hematology
Intervention: ORCA-T ()

CLINICAL TRIAL 24192
An Expanded Access Program for Orca-T Products That Are Out of Specification for Commercial Release
Condition: Malignant Hematology
Intervention: ORCA-T ()

CLINICAL TRIAL 24218
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs. (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; A myeloMATCH Clinical Trial
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 24218
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs. (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; A myeloMATCH Clinical Trial
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 24219
A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)
Condition: Genitourinary
Intervention: Dabogratinib ()

CLINICAL TRIAL 24236
A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: 5-fluorouracil (); Alimta (Pemetrexed); ERAS-0015 (); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Oxaliplatin (); Panitumumab (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxotere (docetaxel); Vectibix (Panitumumab); carboplatin (); cisplatin (); docetaxel (); eloxatin (Oxaliplatin); gemcitabine (); leucovorin ()

CLINICAL TRIAL 24248
Evaluation of the impact of a positive blood culture pager on outcomes for bacteremic and fungemic patients in a cancer hospital
Condition: Multiple
Intervention:

CLINICAL TRIAL 24258
A Phase 1 Study to Evaluate the Safety and Efficacy of DISP-10 in Participants with Advanced Gastrointestinal Cancers
Condition: Immunotherapy
Intervention: Cyclophosphamide (); DV-10 (); Fludarabine (); Idecabtagene Vicleucel ()

CLINICAL TRIAL 24266
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
Condition: Malignant Hematology
Intervention: ACP-196 (Acalabrutinib); Acalabrutinib (); GDC-0199 (Venetoclax); Sonrotoclax (); Venetoclax (); Zanubrutinib ()

CLINICAL TRIAL 24291
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Enrichment, and Dose-Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BLU-924 (SAR449336) as Monotherapy and Combination Therapy in Participants with Advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Harboring KRAS Mutations
Condition: Multiple
Intervention: BLU-924 ()

CLINICAL TRIAL 24299
A study of a mutant-selective inhibitor, CGT6297, in patients with advanced solid tumors harboring PIK3CA mutations
Condition: Multiple
Intervention: CGT6297 ()

CLINICAL TRIAL 24394
A Multi-center, Open-label, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AN9025 in Participants with Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Condition: Multiple
Intervention: AN9025 ()

CLINICAL TRIAL 24417
Neoadjuvant Chemotherapy with or without Cemiplimab (REGN2810) in Sinonasal Squamous Cell Carcinoma: A Randomized Phase 2 Study
Condition: Head & Neck
Intervention: Cemiplimab (); Paraplatin (carboplatin); REGN2810 (Cemiplimab); Radiotherapy (); Taxol (paclitaxel); carboplatin (); cisplatin (); paclitaxel ()

CLINICAL TRIAL 24467
A Retrospective Study of Biomarkers and Survival in Immune Checkpoint Inhibitor (ICI) Associated Neurotoxicity (N-TOX)
Condition: Multiple
Intervention: